Can GLP-1 Medications Help With Sleep Apnea? What the Research Says
PJ's latest reel asks the question out loud, so here's the honest answer. What the randomized trials actually show about GLP-1-type medications and obstructive sleep apnea, what's FDA-approved today, and what's still emerging.
If you caught PJ's latest reel, you saw the question on screen: can GLP-1 medications help with sleep apnea? It's a fair thing to wonder — a lot of people on these medications also live with obstructive sleep apnea, and the two problems often travel together. Here's the honest answer the research supports, with the established part kept carefully separate from the hopeful-but-early part.
First, a plain-English note on what we're talking about
Obstructive sleep apnea (OSA) is when the airway repeatedly collapses during sleep, so breathing keeps pausing through the night. Doctors measure its severity with the apnea-hypopnea index (AHI) — roughly, the number of breathing interruptions per hour. Lower is better.
"GLP-1 medications" is the everyday name for this family, though a couple of the newer ones technically act on more than just the GLP-1 receptor. We'll use the familiar term and flag the difference where it matters.
The established part: tirzepatide is FDA-approved for OSA
This is the solid ground. In December 2024, the FDA approved tirzepatide (Zepbound) for moderate-to-severe OSA in adults who also have obesity — the first medication ever approved to treat sleep apnea. It's meant to be used alongside a reduced-calorie diet and more physical activity.
The approval rested on SURMOUNT-OSA, published in the New England Journal of Medicine in 2024: two 52-week trials in 469 adults.
Key point
In SURMOUNT-OSA, tirzepatide lowered the apnea-hypopnea index by roughly 25 to 29 events per hour, compared with about 5 on placebo — a large difference, and enough that some participants improved by a full severity category.
Tirzepatide is technically a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 drug, but it's the one with an actual OSA approval on the label today. No other medication in this family has that.
The emerging part, piece one: hints of a benefit "beyond" weight loss
Here's where it gets interesting — and where "promising" is the right word, not "proven."
At the CHEST 2026 meeting, researchers looked across the randomized trials of semaglutide and tirzepatide in OSA. The headline AHI improvements held up, and one group described a "profound" reduction in hypoxic burden — a measure of how much oxygen the body loses during those nightly breathing pauses.
The more intriguing thread came from a separate analysis asking how much of the benefit was explained by weight loss alone. For some measures, the answer was: only part of it.
Note
In that analysis, weight loss accounted for only about 54% of the drop in blood pressure and about 42% of the improvement in an inflammation marker — hinting that these medications may help in ways that aren't purely about the number on the scale.
Two honest caveats before anyone gets carried away. First, this "beyond weight loss" signal showed up for blood pressure and inflammation — the researchers' read was that the sleep-apnea (AHI) improvement itself is still largely driven by the weight loss. Second, this is conference-stage evidence relayed through trade coverage, not yet a settled, peer-reviewed verdict. It's a lead worth watching, not a conclusion to bank on.
The emerging part, piece two: retatrutide on the horizon
An investigational drug called retatrutide — a triple-receptor agonist still in trials and not approved for anything yet — reported OSA results in 2026 as part of its larger obesity program (the TRIUMPH-1 trial), published in the New England Journal of Medicine.
Key point
Over 80 weeks, participants saw their apnea-hypopnea index fall by roughly 23 to 34 events per hour across the doses studied, versus about 10 on placebo.
Those are striking numbers. But "investigational" is the operative word: retatrutide isn't available by prescription, and sleep apnea was a pre-specified subgroup of an obesity trial, not the whole study. It's a reason for cautious optimism, not a plan.
So — can GLP-1 medications help with sleep apnea?
Honestly: for some people, the evidence says yes, and that's genuinely encouraging. One of these medications (tirzepatide) is FDA-approved for OSA in people who also have obesity. Others are showing promise that researchers are still working to fully understand.
What this isn't is a shortcut, or a reason to start, stop, or change any medication on your own. Sleep apnea is diagnosed with a sleep study and managed in real medical care — CPAP and other treatments exist for good reasons, and none of this replaces them.
Important
None of this is medical advice. Whether a GLP-1 medication has any role in your own situation — alongside, not instead of, proper sleep-apnea care — is a conversation for you and your healthcare provider. If you snore heavily, wake up gasping, or feel exhausted no matter how long you sleep, those are worth raising with a doctor regardless of any medication.
The bottom line
The research here is real and moving fast. Tirzepatide has crossed from "promising" to "approved" for OSA with obesity; the idea that these medications might help the airway in ways beyond weight loss is a live, hopeful question that isn't settled yet; and the next generation is posting big numbers in trials. All of it points in the same direction — but the next step is a doctor's visit, not a blog post.
Tip
If you're on a GLP-1 and tracking your journey, GLTrax check-ins make it easy to log weight, symptoms, and how you're actually feeling day to day — so when you sit down with your provider to talk about sleep, energy, or anything else, you're working from your real trend instead of memory.
Sourcing note: FDA approval and the tirzepatide figures come from the FDA's December 2024 announcement and SURMOUNT-OSA (Malhotra et al., New England Journal of Medicine, 2024). The "beyond weight loss" blood-pressure and inflammation figures are from research presented at CHEST 2026, as reported by Managed Healthcare Executive (October 2026) — emerging conference data. The retatrutide figures are from the TRIUMPH-1 trial (Jastreboff et al., New England Journal of Medicine, 2026); retatrutide remains investigational and is not FDA-approved.
One question for you: if better sleep — not just a smaller number on the scale — turned out to be one of the payoffs of your GLP-1 journey, how would you know? What would you notice first?
This article is general education, not medical advice. Talk to your healthcare provider about your own treatment.